Actavis prevails in Lialda patent dispute in USA

31 March 2014

US generics major Actavis (NYSE: ACT) says that the US Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Ireland-headquartered Shire's (LSE: SHP) Lialda (mesalamine extended-release tablets) infringes US Patent No 6773,720 (the '720 Patent).

The Appeals Court found that the US District Court for the Southern District of Florida did not correctly construe the claims of the '720 Patent, and remanded the case to the District Court for further proceedings using claim constructions consistent with the Appeals Court's ruling.

Shire’s share price dipped 2.04% to $148.22 in US trading on Friday, when the court decision was announced (but the news was too late to be reflected in trading on the London Stock Exchange).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK